Addressing skyrocketing cancer drug prices comes with tradeoffs: Pick your poison

JAMA Oncology

Volumn 2, Issue 4, 2016, Pages 425-426

  Ramsey, Scott D ^a,b   Lyman, Gary H ^a,b   Bangs, Rick ^c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SWOG ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

DRUG COST; ECONOMICS; HUMAN; NEOPLASMS;

ANTINEOPLASTIC AGENTS; DRUG COSTS; HUMANS; NEOPLASMS;

EID: 85010379645     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.5813     Document Type: Short Survey

References (5)

1. Bach PB. Why Drugs Cost So Much. New York Times. The Opinion Pages. January 14, 2015. http://www.nytimes.com/2015/01/15/opinion/why-drugs-cost-so-much.html?-r=0. Accessed January 12, 2016.
2. Tefferi A, Kantarjian H, Rajkumar SV, et al. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc. 2015;90(8):996-1000.
3. The Pharmaceutical Research and Manufacturers of America (PhRMA). PhRMA statement on government-run plan. http://www.firstwordpharma.com/node/362847#axzz3lGFEKrdH. May 8th, 2009. Accessed September 9, 2015.
4. The Pharmaceutical Research and Manufacturers of America (PhRMA). Focusing on Only 1% of Spending Will Not Solve Nation's Health Care Challenges. http://www.phrma.org/about#sthash.yugZ8wsN.dpufhttp://catalyst.phrma.org/focusing-on-only-1-of-spending-will-not-solve-nations-health-care-challenges. Accessed September 9, 2015.
5. Bach PB. Indication-specific pricing for cancer drugs. JAMA. 2014;312(16):1629-1630.